Regeneron Pharmaceuticals (NASDAQ:REGN) announced its earnings results on Tuesday. The company reported $2.40 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $1.48, American Banking & Market News reports. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 281.70 on Tuesday. Regeneron Pharmaceuticals has a 52-week low of $136.13 and a 52-week high of $319.83. The stock’s 50-day moving average is $299.1 and its 200-day moving average is $262.0. The company has a market cap of $27.522 billion and a P/E ratio of 37.25.
A number of research firms have recently commented on REGN. Analysts at TheStreet reiterated a “positive” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $281.94.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.